|
|
|
| Clinical efficacy of cefoxitin sodium combined with minocycline for treating patients with acute pelvic inflammatory disease and its influence on the inflammatory factor level of the patients |
| Western Theater General Hospital, Chengdu, Sichuan Province, 610000 |
|
|
|
|
Abstract To explore the clinical efficacy and safety of cefoxitin sodium combined with minocycline for treating patients with acute pelvic inflammatory disease (APID), and to study its influence on the inflammatory factor level of the patients. Methods: A total of 90 patients with APID were selected as the research subjects, and were divided into two groups (45 cases in each group) by random number table method from April 2019 to April 2022. The patients in the control group were treated with cefoxitin sodium, and the patients in the observation group were treated with minocycline combined with cefoxitin sodium. The clinical effect, the symptom relief time, the diameter of inflammatory mass, the depth of pelvic effusion, the levels of inflammatory factors, such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP), the hemorheological indicators values, and the incidence of adverse reactions of the patients were compared between the two groups. Results: The effective rate (95.6%) of the patients in the observation group was significantly higher than that (73.3%) of the patients in the control group. The time of leucorrhea returned to normal (5.5±1.1d), the abdominal pain time (5.2±1.0d), the lower abdominal pain relief (5.6±0.5d), the time of pelvic mass disappearance (10.5±3.8d), the diameter of inflammatory mass (1.84±0.53 cm), and the depth of pelvic effusion (0.44±0.12 cm) of the patients in the observation group were significantly shorter than those (8.4±2.2d, 7.4±2.1d, 8.6±2.4d, 15.4±5.3d, 3.11±0.82cm, and 0.80±0.25 cm) of the patients in the control group. The levels of serum inflammatory factors and hemorheology indexes of the patients in the observation group were significantly lower than those of the patients in the control group (all P＜0.05). There was no significant difference in the incidence of adverse reactions (11.1% vs. 6.7%) of the patients between the two groups (P＞0.05). Conclusion: Cefoxitin sodium combined with minocycline for treating the patients with APID can increase the curative effect, reduce the inflammatory factor level, improve the hemorheological indicators and the recovery of symptoms, with higher safety.
|
|
|
|
|
|
|
|
|
